Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01728844 · ClinicalTrials.gov registry record · NA

GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery

A NA study, sponsored by Sunstar Americas.

Completed
Registry status
NA
Development phase
88
Enrollment target

NCT01728844: Completed NA study, sponsored by Sunstar Americas.

NCT01728844 is a NA study that has completed, run by Sunstar Americas. The registered enrollment target is 88 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01728844, a NA study, has completed, sponsored by Sunstar Americas.

COMPLETED
Registry status
NA
Development phase
88 participants
Enrollment target

Study Summary

GUIDOR Growth Factor Enchanted Bone Graft Substitute (GFeBGS) when used in periodontal surgery will shown greater gum and bone regeneration when compare to bone graft substitute alone. Also, to find the optimal dose.

Primary Outcome

The primary effectiveness endpoint is a composite endpoint that considers radiographic and clinical measurements at six months post-implantation: the amount of linear bone growth (LBG), which is assessed with the use of radiographs, and the regain from baseline of clinical attachment level (∆CAL), which is assessed clinically. Linear bone growth (LBG) in a vertical and horizontal direction is determined radiographically at six months post-implantation. The clinical attachment level (CAL) is the

Interventions

  • DEVICE beta-tricalcium phosphate alone
  • DEVICE GFeBGS 0.1%
  • DEVICE GFeBGS 0.3%
  • DEVICE GFeBGS 0.4%

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2012-10
Est. Completion 2014-08
Phase NA
Sunstar Americas

10 total trials

What the finished NCT01728844 record still lists

NCT01728844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 4 interventions - of which beta-tricalcium phosphate alone is the first listed.

NCT01728844 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01728844 about?

NCT01728844 is a clinical study titled "GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery". GUIDOR Growth Factor Enchanted Bone Graft Substitute (GFeBGS) when used in periodontal surgery will shown greater gum and bone regeneration when compare to bone graft substitute alone. Also, to find the optimal dose.

What is the current status of trial NCT01728844?

This trial is currently completed. It is a NA study. The enrollment target is 88 participants. The study started on 2012-10. Estimated completion is 2014-08.

What interventions are being tested in trial NCT01728844?

The interventions under investigation include: beta-tricalcium phosphate alone (DEVICE), GFeBGS 0.1% (DEVICE), GFeBGS 0.3% (DEVICE), GFeBGS 0.4% (DEVICE).

Who is sponsoring clinical trial NCT01728844?

This trial is sponsored by Sunstar Americas, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01728844's enrollment target sits among peer trials

88 972nd of 2000 higher than 1,027 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01728844, the US trial registry maintained by the National Library of Medicine. NCT01728844 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.